AbbVie Announces Updated Results From Phase 2 EPCOREĀ® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
(NYSE:ABBV) Data presented at 13th Society of Hematologic Oncology (SOHO) Annual Meeting NORTH CHICAGO, Ill., Sept. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from the Phase 2 EPCOREĀ® NHL-6 trial (NCT05451810) evaluating the feasibility of dosing and monitoring...
Related Questions
How will the updated Phase 2 results affect AbbVieās nearāterm revenue forecasts and valuation?
What is the expected timeline for regulatory submission and approval of epcoritamab in DLBCL compared to competitorsā pipelines?
How might the outpatient monitoring data influence market adoption, pricing strategy, and competitive positioning against existing DLBCL therapies?